Ashish Chintakuntlawar, MD
Medical Oncology · Scottsdale, AZNPI 1356584262
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,500 of the $1,661 with a category attached, or 90.3%. HRA Pharma RARE Diseases accounts for 90.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in AZ, where the typical reported total is $8,518.
Across 2 payments — averaging $830.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- HRA Pharma RARE Diseases$2K
- AVEO Pharmaceuticals, Inc.$161
Across 21 payments — averaging $6216.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$75K
- Eisai Inc.$35K
- Regeneron$12K
- Pfizer$8K
What the payments were for
- Consulting fees$1,50090%
- Food & beverage$16110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| HRA Pharma RARE Diseases | 1 | $1,500 |
| AVEO Pharmaceuticals, Inc. | 1 | $161 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,661 in reported general payments places this provider in the 30th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 86 | $557 |
| Prochlorperazine Maleate | 50 | $423 |
| Ondansetron Hcl | 42 | $263 |
| Levothyroxine Sodium | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Scottsdale
- Daniel von HoffScottsdale$165K
- Erkut BorazanciScottsdale$31K
- Rajinder GroverScottsdale$13K
- Rishi AgarwalScottsdale$12K
- Walter KimScottsdale$6K
- John BibbScottsdale$713
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.